This page lists the SEC filings reported by Baker Brothers Advisors.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2020-07-28 | BAKER BROS. ADVISORS LP | Kiniksa Pharmaceuticals, Ltd. | 2,880,870 | 9.2% | EDGAR |
| SC 13D/A | 2020-07-17 | BAKER BROS. ADVISORS LP | BeiGene, Ltd. | 173,503,441 | 14.9% | EDGAR |
| SC 13D/A | 2020-05-19 | BAKER BROS. ADVISORS LP | SEATTLE GENETICS INC /WA | 47,366,002 | 27.3% | EDGAR |
| SC 13D/A | 2020-05-18 | BAKER BROS. ADVISORS LP | Kiniksa Pharmaceuticals, Ltd. | 2,874,617 | 11.4% | EDGAR |
| SC 13D/A | 2020-05-08 | BAKER BROS. ADVISORS LP | SEATTLE GENETICS INC /WA | 49,116,002 | 28.4% | EDGAR |
| SC 13D/A | 2020-04-29 | BAKER BROS. ADVISORS LP | INCYTE CORP | 32,146,257 | 14.8% | EDGAR |
| SC 13D/A | 2020-04-24 | BAKER BROS. ADVISORS LP | SEATTLE GENETICS INC /WA | 50,174,318 | 29.1% | EDGAR |
| SC 13D | 2020-03-25 | BAKER BROS. ADVISORS LP | Zymeworks Inc. | 4,862,414 | 10.0% | EDGAR |
| SC 13D/A | 2020-02-26 | BAKER BROS. ADVISORS LP | Kodiak Sciences Inc. | 11,574,537 | 26.3% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | Aeglea BioTherapeutics, Inc. | 1,713,604 | 5.9% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | AMARIN CORP PLC\UK | 34,496,685 | 9.6% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | Ascendis Pharma A/S | 3,390,270 | 7.1% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | CymaBay Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | HERON THERAPEUTICS, INC. /DE/ | 7,979,853 | 8.7% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | Principia Biopharma Inc. | 1,808,684 | 5.5% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | Krystal Biotech, Inc. | 1,034,674 | 6.0% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | BIOCRYST PHARMACEUTICALS INC | 15,797,212 | 9.9% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | Invitae Corp | 9,222,078 | 9.5% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | Zymeworks Inc. | 4,181,872 | 10.0% | EDGAR |
| SC 13G/A | 2020-02-14 | BAKER BROS. ADVISORS LP | CONTRAFECT Corp | 5,553,599 | 3.5% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.